ライフサイエンスコーパス: cardiac failure

1 e to exacerbation of chronic lung disease or cardiac failure).

2 new therapeutic option against post-infarct cardiac failure.

3 provides a plausible molecular mechanism for cardiac failure.

4 leading to impaired ventricular function and cardiac failure.

5 nts one of the most common causes leading to cardiac failure.

6 d nature of the stress on the development of cardiac failure.

7 culatory support in patients with refractory cardiac failure.

8 rt is presented for patients with refractory cardiac failure.

9 n culminating in death due to respiratory or cardiac failure.

10 blood cell transfusions to avoid death from cardiac failure.

11 rches, aortic arch arteries, and no signs of cardiac failure.

12 unction are common to virtually all forms of cardiac failure.

13 minent death from irreversible biventricular cardiac failure.

14 key role in the pathogenesis of DOX-induced cardiac failure.

15 ents develop cardiomyopathy, and many die of cardiac failure.

16 ted with LV dilatation, indicating incipient cardiac failure.

17 s to premature death from respiratory and/or cardiac failure.

18 and hypertension is the most common cause of cardiac failure.

19 toxemia, myocardial cytokine production, and cardiac failure.

20 competent, and this value was not changed by cardiac failure.

21 ost commonly related to iatrogenic causes or cardiac failure.

22 s die in utero at midgestation with signs of cardiac failure.

23 37 patients subsequently developed new-onset cardiac failure.

24 melaena, and evidence of hepatic disease or cardiac failure.

25 heart; each contributes to the evolution of cardiac failure.

26 en and 12 men undergoing transplantation for cardiac failure.

27 and real decay are systematically altered by cardiac failure.

28 rtrophy can proceed by unknown mechanisms to cardiac failure.

29 m of the ventricular chambers and consequent cardiac failure.

30 rage 50% of the left ventricle, and produced cardiac failure.

31 vinculin can also provoke HCM, causing acute cardiac failure.

32 One patient died of anthracycline-induced cardiac failure.

33 otic reorganization that eventually leads to cardiac failure.

34 umans, and is upregulated by hypertrophy and cardiac failure.

35 LVEF remained stable with no new arrhythmias/cardiac failure.

36 d Gas signaling and thereby protects against cardiac failure.

37 transition from compensatory hypertrophy to cardiac failure.

38 ife, she developed cardiomegaly and signs of cardiac failure.

39 2 may increase susceptibility to DOX-induced cardiac failure.

40 yocyte apoptosis and susceptibility to overt cardiac failure.

41 d a duplication of chromosome 6p and died of cardiac failure.

42 models of acute diseases such as kidney and cardiac failure.

43 to pressure overload-induced hypertrophy and cardiac failure.

44 , pulmonary vascular disease, and associated cardiac failure.

45 red cardiac transplantation and four died of cardiac failure.

46 tivated and can depress function, leading to cardiac failure.

47 0.35 ng/mL) (p = .14) or those patients with cardiac failure (0.21 ng/mL).

48 e, 2 patients died; 1 from stroke and 1 from cardiac failure (30-day mortality: 7.4%).

49 rred through week 24 were anaemia (10 [5%]), cardiac failure (5 [2%]), pyrexia (4 [2%]), and pneumoni

50 bits HIF-1alpha synthesis, resulted in rapid cardiac failure after TAC.

51 tudy, 3 died (from sepsis, tuberculosis, and cardiac failure, all in patients who received 100 mg gol

52 thostimulation may worsen the progression of cardiac failure, although the nature and mechanisms of s

53 Obesity-related HFpEF is a genuine form of cardiac failure and a clinically relevant phenotype that

54 ages for the full cardiac cycle in dogs with cardiac failure and a left bundle conduction delay.

55 nic lethal, with death at mid-gestation from cardiac failure and a unique constellation of developmen

56 nal sodium and water retention, particularly cardiac failure and cirrhosis, have been suggested to ha

57 Snrk in cardiomyocytes (Snrk cmcKO) leads to cardiac failure and death by 8 to 10 months.

58 ly debilitating DCM that ultimately leads to cardiac failure and death, whereas autosomal dominant mu

59 y and are associated with the development of cardiac failure and death.

60 Ndufs6(gt/gt) mice are at increased risk of cardiac failure and death.

61 roper myocardial development with subsequent cardiac failure and embryonic demise.

62 erous endocrine diseases, hepatic cirrhosis, cardiac failure and even death.

63 sociated with disease progression leading to cardiac failure and fibrosis.

64 n their cirrhotic liver who developed severe cardiac failure and have iron deposits in the heart, des

65 It is up-regulated in cardiac failure and hypertrophy and represses expression

66 However, during cardiac failure and hypertrophy, ANF expression can reap

67 d autonomic neuropathy often with associated cardiac failure and is due to dominantly inherited trans

68 (betaAR) blockade is a standard therapy for cardiac failure and ischemia.

69 ces underlie human medical disorders such as cardiac failure and pulmonary injury.

70 ient zebrafish had skeletal muscle weakness, cardiac failure and small heads.

71 eneration, CV Prevention & Health Promotion, Cardiac Failure, and Cardiomyopathies (1-70).

72 eneration, CV Prevention & Health Promotion, Cardiac Failure, and Cardiomyopathies.

73 may lead to pump failure, as in hypertensive cardiac failure, and could explain features of breast ca

74 es including stroke, coronary heart disease, cardiac failure, and endstage renal disease.

75 myocardium of patients affected by end-stage cardiac failure, and whether these cells can be harveste

76 ons, liver developmental delay, and die from cardiac failure around embryonic day (E) 14.5 pc.

77 times as high in the hearts of patients with cardiac failure as in the normal hearts, whereas labelin

78 heir medium and large arteries and expire of cardiac failure as neonates, while calciphylaxis of CKD

79 esis and suggest a combination of anemia and cardiac failure as the cause of embryonic lethality in t

80 ac hypertrophy at 4 weeks and progressing to cardiac failure at 8 weeks using whole-cell patch-clamp

81 uption of mitochondrial fusion causes lethal cardiac failure at a time corresponding to 3 or 4 cycles

82 rative disease that frequently culminates in cardiac failure at an early age.

83 had clinical progression (eg, admission for cardiac failure, atrial fibrillation, and syncope).

84 day11.5 observed with PBP null mutation was cardiac failure because of noncompaction of the ventricu

85 e effects include electrolyte abnormalities, cardiac failure, bleeding diathesis, and phlebitis.

86 hG alpha h activity is associated with human cardiac failure but that the mechanism differs between i

87 sion of fetal marker genes characteristic of cardiac failure, but no significant hypertrophy at the o

88 Ninety patients had developed cardiac failure by 1 yr of dialysis therapy.

89 ollow-up after normalization is warranted as cardiac failure can recur.

90 n at levels so extreme as to elicit signs of cardiac failure, can be reversed by natural regenerative

91 ventions, CVD Prevention & Health Promotion, Cardiac Failure, Cardiomyopathies, Genetics, Omics, & Ti

92 ventions, CVD Prevention & Health Promotion, Cardiac Failure, Cardiomyopathies, Genetics, Omics, & Ti

93 he sections: Basic & Translational Research, Cardiac Failure, Cardiomyopathies/Myocardial & Pericardi

94 he sections: Basic & Translational Research, Cardiac Failure, Cardiomyopathies/Myocardial & Pericardi

95 Increasing the heart rate of the fetus with cardiac failure caused by complete AV block (CAVB) may a

96 Only congestive cardiac failure (CCF) was an independent predictor of si

97 ) were rheumatic heart disease or congestive cardiac failure, chronic obstructive pulmonary disease,

98 ogy of edema as occurs in conditions such as cardiac failure, cirrhosis, and pregnancy.

99 7 g/m(2) in those who subsequently developed cardiac failure compared with 0 g/m(2) among those who d

100 increased risk of myocardial infarction and cardiac failure compared with nondiabetic age-matched in

101 previous medical conditions predisposing to cardiac failure: congestive heart failure (CHF; 6 [27%]

102 reduced synthesis may blunt this pathway in cardiac failure, contributing to dampening of the beta-a

103 ron accumulation in their liver explants and cardiac failure despite the absence of HFE mutations.

104 ular disease (angina, myocardial infarction, cardiac failure, diabetes and peripheral vascular diseas

105 resonance imaging (MRI) agents for cancer or cardiac failure diagnosis and therapy monitoring through

106 sed despite follow-up and treatment, causing cardiac failure, diplegia, and neurogenic bladder.

107 It is therefore possible to attribute cardiac failure directly to particular genes by ruling o

108 ly lethal hyperacute respiratory, renal, and cardiac failure due to increased abdominal pressure.

109 eometry and blocked the development of acute cardiac failure during a dobutamine-mediated stress prot

110 MEF2A knock-out mice develop cardiac failure during the perinatal period with mutant

111 Homozygous mice die at embryonic day 14.5 in cardiac failure, exhibiting abnormalities not seen in NM

112 nolinone derivative used in the treatment of cardiac failure, exhibits immunomodulatory, anti-inflamm

113 one pain (one [1%] vs four [2%]), congestive cardiac failure (four [2%] vs two [1%]), myocardial infa

114 Contraindications such as infection and cardiac failure further add to the number of patients wh

115 vant genetic mouse models of hypertrophy and cardiac failure, Galphaq overexpression and human famili

116 Cardiac failure has a principal underlying aetiology of

117 ongestive heart failure, pulmonary edema, or cardiac failure (hazard ratio for the comparison of the

118 bolic risk prediction scores such as CHADS2 (Cardiac Failure, Hypertension, Age, Diabetes, and Stroke

119 rly, there was an increase in mean CHADS(2) [cardiac failure, hypertension, age, diabetes, stroke (do

120 failure, hepatocellular carcinoma, diabetes, cardiac failure, impotence, and arthritis.

121 ns, and evidence for ECMO in respiratory and cardiac failure in adults as well as potential applicati

122 oxygenation (ECMO) for both respiratory and cardiac failure in adults is evolving rapidly.

123 ygenation (ECMO) is used for respiratory and cardiac failure in children but is complicated by bleedi

124 lead to worsening pulmonary hypertension and cardiac failure in children, and it is frequently lethal

125 Cardiac failure in elderly patients is commonly interpre

126 inhibitor phospholamban (PLN) has prevented cardiac failure in experimental dilated cardiomyopathy a

127 shortening with age could also contribute to cardiac failure in humans, opening the possibility for n

128 aged diseased hearts and the development of cardiac failure in humans.

129 amin D supplementation might protect against cardiac failure in older people but does not appear to p

130 %) in the olaparib plus paclitaxel group and cardiac failure in one patient (<1%) in the placebo plus

131 mon in both cardiac hypertrophy and failure; cardiac failure in particular is associated with a signi

132 the wall 8 days after coronary occlusion and cardiac failure in rats.

133 w-up (1 of unexplained sudden death and 1 of cardiac failure in the context of septicemia, respective

134 y artery disease is the most common cause of cardiac failure in the Western world, and to date there

135 of the beta(2)AR caused rapidly progressive cardiac failure in this model.

136 d by transaortic constriction and consequent cardiac failure in vivo.

137 These results have implications for cardiac failure in which force-frequency modulation is b

138 Myocarditis is a leading cause of sudden cardiac failure in young adults.

139 ys a critical role in the pathophysiology of cardiac failure, including the modulation of neovascular

140 rog/kg per min, i.v.) to conscious dogs with cardiac failure induced by chronic tachycardia pacing.

141 Cardiac failure is a frequent cause of death in the agin

142 Cardiac failure is a major cause of death in patients wi

143 For example, cardiac failure is a predominant cause of death in neona

144 Cardiac failure is characterised by the loss of cardiomy

145 editary hemorrhagic telangiectasia (HHT) and cardiac failure is liver transplant.

146 m shift for the treatment of respiratory and cardiac failure is tempered by a need for evidence to su

147 Cardiac failure is the most common cause of mortality in

148 Acute cardiac failure may also be a cause of epileptic sudden

149 Patients presented with cardiac failure (median age, 75 [range, 59-90] years).

150 plain the ineffectiveness of nesiritide as a cardiac failure medication.

151 for vitamin D compared with no vitamin D for cardiac failure, MI, and stroke were 0.75 (0.58, 0.97),

152 e placebo or control for on-study events for cardiac failure, MI, and stroke were 0.82 (0.58, 1.15),

153 ed whether vitamin D supplementation reduces cardiac failure, myocardial infarction (MI), and stroke

154 d to secondary sclerosing cholangitis (n=1), cardiac failure (n=1), and sepsis (n=3).

155 , and two were considered treatment-related (cardiac failure [n=1] in the buparlisib group and unknow

156 sepsis [n=2], septic shock [n=1], congestive cardiac failure [n=1], and unknown cause [n=1]) versus o

157 Cardiac failure occurs when the heart fails to adapt to

158 an important mechanism in the development of cardiac failure of either ischemic or nonischemic origin

159 ived the anti-CD3 rIT died from pneumonia or cardiac failure on days 15 and 23.

160 ung infection (three [1%] patients vs none), cardiac failure (one [<1%] vs one [<1%]), and colitis (t

161 -release syndrome (one attributed to grade 5 cardiac failure); one had fatal respiratory failure.

162 in patients who present with recent onset of cardiac failure or arrhythmia.

163 2.5 (10.1) years, and the mean CHA2DS2-VASc (cardiac failure or dysfunction, hypertension, age >/=75

164 The CHA2DS2-VASc (cardiac failure or dysfunction, hypertension, age 65-74

165 For example, in patients with cardiac failure or liver disease and in pregnant women,

166 en cardiac output is low (e.g. in low output cardiac failure) or high (e.g. cirrhosis or pregnancy).

167 he increased risk for myocardial infarction, cardiac failure, or stroke, which are the most common ca

168 rocephalus were risk factors for both severe cardiac failure (p = 0.01 and p = 0.04, respectively) an

169 In disorders such as cardiac failure, PDE5A upregulation may contribute to a

170 dex and fractional shortening and subsequent cardiac failure persisted after adjusting for baseline a

171 NF-ATc null mutant mice die in utero of cardiac failure, precluding analysis of the role of NF-A

172 y (MCA) "pseudofeeders" were correlated with cardiac failure, pulmonary hypertension, and encephaloma

173 able physicians to treat patients with acute cardiac failure refractory to conventional therapy.

174 state of hypertensive load to that of overt cardiac failure remain largely unknown.

175 hemical test abnormalities may be related to cardiac failure, resulting from intrinsic liver disease,

176 nt), three grade 2 treatment-related events (cardiac failure, sarcoidosis, and foot fracture, all in

177 Cardiac failure, shock, atrioventricular block and atria

178 tly licensed for hypertension and congestive cardiac failure, showed neuroprotective and myeloprotect

179 rably attenuates hemodynamic derangements of cardiac failure that develop during exercise in individu

180 ut heart failure (HF) is an unusual cause of cardiac failure that has not been well-characterized.

181 he ventricular myocardium triggered signs of cardiac failure that were not observed after partial ven

182 After the documentation of cardiac failure, the unaffected myocytes were enzymatica

183 l remodeling during the early progression to cardiac failure through the release of reactive oxygen s

184 a levels displayed substantial resistance to cardiac failure upon pressure overload.

185 Survival in moribund patients with cardiac failure was 48% in 105 children and 33% in 31 ad

186 Thus, cardiac failure was associated with decreased myocardial

187 ative incidence of the composite category of cardiac failure was higher in the dutasteride group than

188 imilar between groups except that congestive cardiac failure was more common in the syncope group.

189 Cardiac failure was noted to have the highest incidence

190 in renin-dependent hypertension and chronic cardiac failure when circulating Ang II is elevated.

191 CV 30/87-infected pigs developed acute fatal cardiac failure, whereas the rest of the pigs were overt

192 However, it is often associated with cardiac failure, which once manifests carries a poor pro

193 cardiac arrhythmia, metabolic acidosis, and cardiac failure, which resulted in death.

194 iatric disorders as well as the treatment of cardiac failure with beta blockers.